Literature DB >> 24477798

Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study.

Zheng Chang1, Paul Lichtenstein1, Brian M D'Onofrio2, Arvid Sjölander1, Henrik Larsson1.   

Abstract

IMPORTANCE: Studies have shown that attention-deficit/hyperactivity disorder (ADHD) is associated with transport accidents, but the magnitude of the association remains unclear. Most important, it is also unclear whether ADHD medication reduces this risk.
OBJECTIVES: To estimate the association between ADHD and the risk of serious transport accidents and to explore the extent to which ADHD medication influences this risk among patients with ADHD. DESIGN, SETTING, AND PARTICIPANTS: In total, 17,408 patients with a diagnosis of ADHD were observed from January 1, 2006, through December 31, 2009, for serious transport accidents documented in Swedish national registers. The association between ADHD and accidents was estimated with Cox proportional hazards regression. To study the effect of ADHD medication, we used stratified Cox regression to compare the risk of accidents during the medication period with the risk during the nonmedication period within the same patients. MAIN OUTCOMES AND MEASURES: Serious transport accident, identified as an emergency hospital visit or death due to transport accident.
RESULTS: Compared with individuals without ADHD, male patients with ADHD (adjusted hazard ratio, 1.47; 95% CI, 1.32-1.63) and female patients with ADHD (1.45; 1.24-1.71) had an increased risk of serious transport accidents. In male patients with ADHD, medication was associated with a 58% risk reduction (hazard ratio, 0.42; 95% CI, 0.23-0.75), but there was no statistically significant association in female patients. Estimates of the population-attributable fractions suggested that 41% to 49% of the accidents in male patients with ADHD could have been avoided if they had been receiving treatment during the entire follow-up. CONCLUSIONS AND RELEVANCE: Attention-deficit/hyperactivity disorder is associated with an increased risk of serious transport accidents, and this risk seems to be possibly reduced by ADHD medication, at least among male patients. This should lead to increased awareness among clinicians and patients of the association between serious transport accidents and ADHD medication.

Entities:  

Mesh:

Year:  2014        PMID: 24477798      PMCID: PMC3949159          DOI: 10.1001/jamapsychiatry.2013.4174

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  31 in total

1.  Attributable risk function in the proportional hazards model for censored time-to-event.

Authors:  Ying Qing Chen; Chengcheng Hu; Yan Wang
Journal:  Biostatistics       Date:  2006-02-14       Impact factor: 5.899

2.  The occurrence of lung cancer in man.

Authors:  M L LEVIN
Journal:  Acta Unio Int Contra Cancrum       Date:  1953

Review 3.  Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline.

Authors:  Tobias Banaschewski; David Coghill; Paramala Santosh; Alessandro Zuddas; Philip Asherson; Jan Buitelaar; Marina Danckaerts; Manfred Döpfner; Stephen V Faraone; Aribert Rothenberger; Joseph Sergeant; Hans-Christoph Steinhausen; Edmund J S Sonuga-Barke; Eric Taylor
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-05-05       Impact factor: 4.785

Review 4.  A review of driving risks and impairments associated with attention-deficit/hyperactivity disorder and the effects of stimulant medication on driving performance.

Authors:  Russell A Barkley; Daniel Cox
Journal:  J Safety Res       Date:  2007-02-15

5.  Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning.

Authors:  Russell A Barkley; Kevin R Murphy; George I Dupaul; Tracie Bush
Journal:  J Int Neuropsychol Soc       Date:  2002-07       Impact factor: 2.892

6.  Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder.

Authors:  Henrik Larsson; Eleonore Rydén; Marcus Boman; Niklas Långström; Paul Lichtenstein; Mikael Landén
Journal:  Br J Psychiatry       Date:  2013-05-23       Impact factor: 9.319

7.  Traffic accident involvement rates by driver age and gender.

Authors:  D L Massie; K L Campbell; A F Williams
Journal:  Accid Anal Prev       Date:  1995-02

Review 8.  Driving impairments in teens and adults with attention-deficit/hyperactivity disorder.

Authors:  Russell A Barkley
Journal:  Psychiatr Clin North Am       Date:  2004-06

9.  Distractions and the risk of car crash injury: the effect of drivers' age.

Authors:  Lawrence T Lam
Journal:  J Safety Res       Date:  2002

Review 10.  Attention-deficit/hyperactivity disorder (ADHD) and driving risk: a review of the literature and a methodological critique.

Authors:  Laurence Jerome; Liat Habinski; Alvin Segal
Journal:  Curr Psychiatry Rep       Date:  2006-10       Impact factor: 8.081

View more
  98 in total

1.  Familial Liability to Epilepsy and Attention-Deficit/Hyperactivity Disorder: A Nationwide Cohort Study.

Authors:  Isabell Brikell; Laura Ghirardi; Brian M D'Onofrio; David W Dunn; Catarina Almqvist; Søren Dalsgaard; Ralf Kuja-Halkola; Henrik Larsson
Journal:  Biol Psychiatry       Date:  2017-08-12       Impact factor: 13.382

Review 2.  Genetic Influence on Efficacy of Pharmacotherapy for Pediatric Attention-Deficit/Hyperactivity Disorder: Overview and Current Status of Research.

Authors:  Nada A Elsayed; Kaila M Yamamoto; Tanya E Froehlich
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

Review 3.  Risks and Benefits of Attention-Deficit/Hyperactivity Disorder Medication on Behavioral and Neuropsychiatric Outcomes: A Qualitative Review of Pharmacoepidemiology Studies Using Linked Prescription Databases.

Authors:  Zheng Chang; Laura Ghirardi; Patrick D Quinn; Philip Asherson; Brian M D'Onofrio; Henrik Larsson
Journal:  Biol Psychiatry       Date:  2019-04-17       Impact factor: 13.382

4.  The benefit of stimulants in reducing driving risk in adult drivers with ADHD.

Authors:  Laurence Jerome
Journal:  CMAJ       Date:  2014-06-10       Impact factor: 8.262

5.  Traffic Crashes, Violations, and Suspensions Among Young Drivers With ADHD.

Authors:  Allison E Curry; Benjamin E Yerys; Kristina B Metzger; Meghan E Carey; Thomas J Power
Journal:  Pediatrics       Date:  2019-05-20       Impact factor: 7.124

6.  Adult Attention-Deficit Hyperactivity Disorder is Hard to Diagnose and is Undertreated.

Authors:  Laurence Jerome
Journal:  Can J Psychiatry       Date:  2016-01       Impact factor: 4.356

7.  Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.

Authors:  Mark L Wolraich; Joseph F Hagan; Carla Allan; Eugenia Chan; Dale Davison; Marian Earls; Steven W Evans; Susan K Flinn; Tanya Froehlich; Jennifer Frost; Joseph R Holbrook; Christoph Ulrich Lehmann; Herschel Robert Lessin; Kymika Okechukwu; Karen L Pierce; Jonathan D Winner; William Zurhellen
Journal:  Pediatrics       Date:  2019-10       Impact factor: 7.124

Review 8.  Annual research review: Optimal outcomes of child and adolescent mental illness.

Authors:  E Jane Costello; Barbara Maughan
Journal:  J Child Psychol Psychiatry       Date:  2014-12-12       Impact factor: 8.982

9.  ADHD, depression, and motor vehicle crashes: A prospective cohort study of continuously-monitored, real-world driving.

Authors:  Paula A Aduen; Michael J Kofler; Dustin E Sarver; Erica L Wells; Elia F Soto; Daniel J Cox
Journal:  J Psychiatr Res       Date:  2018-03-06       Impact factor: 4.791

10.  Dosage of methylphenidate and traumatic brain injury in ADHD: a population-based study in Taiwan.

Authors:  Yin-To Liao; Yao-Hsu Yang; Ting-Yu Kuo; Hsin-Yi Liang; Kuo-You Huang; Tsu-Nai Wang; Yena Lee; Roger S McIntyre; Vincent Chin-Hung Chen
Journal:  Eur Child Adolesc Psychiatry       Date:  2017-08-30       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.